Background: At present, there are only few objective quality criteria for the treatment of peritoneal carcinomatosis using cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (HIPEC). Method and Results: However, because this therapy is associated with significant morbidity and mortality, such quality criteria are quite important. Accreditation of peritoneal carcinomatosis centers by the German Society for General and Visceral Surgery was a first step towards establishing these clinics. Conclusion: One key requirement for accreditation is membership in the German Peritoneal Carcinomatosis Registry. This prospective database provides a collation and evaluation of the epidemiological and therapeutic factors relating to this disease.

Keywords:
Peritoneal carcinomatosis, German HIPEC registry, Accreditation
1.
Glehen O, Osinsky D, Cotte E, Kwiatkowski F. Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, Francois Y, Vignal J, Gilly FN: Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863-869.
2.
Yan TD, Links M, Fransi S: Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy - a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007;14:2270-2280.
3.
Moran BJ, Mukherjee A, Sexton R: Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100-104.
4.
Smeenk RM, Verwaal VJ, Zoetmulder FA: Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 2007;94:1408-1414.
5.
Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH: Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622-2629.
6.
Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH: Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790-796.
7.
Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH: Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631-636.
8.
González Bayón L, Sugarbaker PH, Gonzalez Moreno S, Vazquez Vde L, Alves S, Moran BJ: Initiation of a program in peritoneal surface malignancy. Surg Oncol Clin N Am 2003;12:741-753.
9.
Mohamed F, Moran BJ: Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer 2009;15:196-199.
10.
Chua TC, Yan TD, Saxena A, Morris DL: Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 2009;249:900-907.
11.
Moran BJ: Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf) 2006;28:375-378.
12.
Cavaliere F, Valle M, De Rosa B, et al: Peritonectomy and chemohyperthermia in the treatment of peritoneal carcinomatosis: learning curve. Suppl Tumori 2005;3:119-121.
13.
Moradi BN 3rd, Esquivel J: Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2009;100:293-296.
14.
Prystowsky JB, Bordage G, Feinglass JM: Patient outcomes for segmental colon resection according to surgeon's training, certification, and experience. Surgery 2002;132:663-670.
15.
Scheidbach H, Kube R, Schmidt U, Robra BP, Gastinger I, Lippert H: Quality evaluation in colorectal surgery in dependence on health-care categories of hospitals - minor differences in outcome with room for improvement in process quality. Gesundheitswesen 2011;73:134-139.
16.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; French Surgical Association: Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010;116:5608-5618.
17.
Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D; Association Française de Chirurgie: Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370-2377.
18.
Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O; Association Française de Chirurgie: Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010;36:456-462.
19.
Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010;28:63-68.
© 2013 S. Karger GmbH, Freiburg
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.